CLINICAL_TRIALS trial_result · 2019-08-13

Clinical Trial Update: Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years [Phase 3]

A Phase 3 trial assessing SHP465 6.25 mg for ADHD in children aged 6-12 has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2019-08-13